Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Patients With Advanced Stage Newly Diagnosed Hodgkin Lymphoma

Next Previous
X
Search
Trial Profile

An Open-Label Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Patients With Advanced Stage Newly Diagnosed Hodgkin Lymphoma

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 29 Jan 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Brentuximab vedotin (Primary) ; Dacarbazine; Doxorubicin; Vinblastine
  • Indications Hodgkin's disease
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Takeda Oncology

    • Most Recent Events

    • 02 Jan 2024 Planned End Date changed from 24 Sep 2021 to 24 Sep 2029.
    • 02 Jan 2024 Status changed from completed to active, no longer recruiting.
    • 13 Dec 2022 Results using data from NCT01492088 and NCT02979522 to develop PPK models , identifying factors impacting the pharmacokinetics of ADC and MMAE, and exposure response analyses assessing the risk benefit profiles of brentuximab vedotin combined with chemotherapy, presented at the 64th American Society of Hematology Annual Meeting and Exposition

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top